StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Provectus Biopharmaceuticals's enterprise value was $19.38M on Oct 19, 2026, against $29.86M a year earlier. Over the last 5 years it ranged from $19.38M to $82.99M, with a median of $36.39M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Oct 19, 2026$19.38M-17.3%
2025Dec 31, 2025$23.43M-53.4%
2024Dec 31, 2024$50.29M+26.0%
2023Dec 29, 2023$39.91M-11.8%
2022Dec 30, 2022$45.24M+98.3%
2021Dec 31, 2021$22.82M+3.4%
2020Dec 31, 2020$22.07M-8.2%
2019Dec 31, 2019$24.05M+26.9%
2018Dec 31, 2018$18.94M-37.3%
2017Dec 29, 2017$30.19M–
2016Dec 30, 2016-$300.17K-100.5%
2015Dec 31, 2015$60.92M-51.8%
2014Dec 31, 2014$126.47M-61.6%
2013Dec 31, 2013$329.08M+447.6%
2012Dec 31, 2012$60.09M-23.0%
2011Dec 30, 2011$78.00M–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?